Clinical Trial Search

Primary: Change in Serum Osteocalcin From Baseline to End of Study in Patients With Relapsed/Refractory Multiple Myeloma. — 20.00 ng/ML

Primary: Clinical Benefit Rate of the Combination of Enzalutamide/ Fulvestrant — 7 Participants

Primary: Recommended Phase 2 Dose for Enzastaurin Plus Erlotinib Combination Therapy (Assess the Tolerated Dose of the Combination Erlotinib and Enzastaurin) — 500; 150…

Primary: Progression-Free Survival (PFS) — 3.5; 4.3 months — p=0.469

Primary: Change From Baseline in the Numerical Rating Score (NRS) for Pruritus (Worst Itch) — 7.3; 7.26; 4.27; 4.6 score on a scale — p== 0.249

Primary: Maximum Tolerated Dose (MTD) (Phase 1) — 25 micrograms

Primary: Insulin Sensitivity at 6 Months From Baseline — 9.9; 6.4 (mL/kg/min)/(microIU/mL) — p=<0.05

Primary: Progression-free Survival — 2.1; NA years — p=0.015

Primary: Mean Change From Baseline in Best Corrected Visual Acuity Letter Score — 11.4; 13.8 letters — p=0.288

Primary: Change From Baseline in Average Daily Pain Score at Week 6 — 6.4; 5.9; -2.3; -1.1 units on a scale

Primary: Number of Participants With Dose-limiting Toxicities in the Dose-escalation Phase — 0; 0; 0; 0 Participants

Primary: Composite of Memory t Scores — 39.5; 39.7 score on a scale

Primary: Time to Disease Progression — 4.6; 6.0; 4.1 months — p=0.40

Primary: Subjects Alive and Off of Oxygen at Day 14 — 12; 9 Participants

Primary: Change From Baseline in Average Daily Pain Score at Week 6 — 5.5; 5.6; -1.4; -1.0 units on a scale